Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06334991 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableEnrollment increased: 10 → 20 participantsTrial status changed: Recruiting → Active, Not Recruiting · Primary and study completion moved earlier from Mar 2028 to Oct 2027 · Secondary endpoints: 1 to 2 · 3 morev7Show 6 more changesShow less
Trial status changed: Recruiting → Active, Not Recruiting
Primary and study completion moved earlier from Mar 2028 to Oct 2027
NotablePrimary completion pushed from Mar 30, 2026 to Mar 2028Completion pushed from Mar 30, 2027 to Mar 2028 · Site details revised at 1 of 3 sitesv6Show 2 more changesShow less
Completion pushed from Mar 30, 2027 to Mar 2028
Site details revised at 1 of 3 sites
MinorSite contacts updated at 1 of 3 sitesv5
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 3v4Show 1 more changeShow less
Study sites: 0 to 3
NotableStart date: Jul 1, 2024 to Aug 23, 2024v3
NotableStart date: May 1, 2024 to Jul 1, 2024v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).